Phosphodiesterase 4 inhibitors vs placebo
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors leads to lower number of participants with 1 or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOR 0.78 [0.73, 0.84]27 studies · 20382 participantsHigh